Impel Pharmaceuticals’ Chapter 11 cases closed on March 25, 2025, under the final decree Dkt. 459, following an asset sale and an effective liquidation plan. The decree directs required plan payments and distributions; the administrator’s February 21, 2025 final-decree motion Dkt. 456 identified final tax reporting, deregistration, and dissolution as remaining wind-down tasks.

Impel Pharmaceuticals’ Chapter 11 cases closed on March 25, 2025, under the final decree Dkt. 459, following an asset sale and an effective liquidation plan. The decree directs required plan payments and distributions; the administrator’s February 21, 2025 final-decree motion Dkt. 456 identified final tax reporting, deregistration, and dissolution as remaining wind-down tasks.